



## **SYNAGEVA BIOPHARMA ADDS TWO NEW INVESTORS AND ANNOUNCES ADDITIONAL FUNDING**

**Waltham, MA., May 5, 2009** --[Synageva BioPharma Corp.](#), a privately held biopharmaceutical company, announced today that it has added two new investment groups as part of the second closing of its financing. This transaction follows the initial funding of \$30 million announced on April 15, 2009. The total financing raised between the two closings is more than \$33 million. The new investor groups participating in the second closing are Yasuda Enterprise Development Co., Ltd., based in Tokyo, Japan, and Hunt BioVentures, based in Dallas, Texas.

"We are delighted to have these two highly successful and established investment groups join our existing group of world-class equity firms, and also to have them be a part of the Synageva community," stated Sanj K. Patel, Synageva's President and CEO.

Yasuda Enterprise Development Co., Ltd., is one of the largest and most experienced venture capital firms in Japan. With more than \$900 million currently under management, Yasuda has supported more than 200 IPOs since its inception. Yasuda has built strong networks with pharmaceutical industries in Japan as well as investor bases in Asia and provides international business development as well as syndication support to its portfolio companies.

Sakae Asanuma, General Manager of the Yasuda Enterprise Development Company stated, "We are extremely excited to be a part of the Synageva opportunity. The company's unique proprietary platform technology, which generates both next generation/novel biologics and bio-similars, has enormous potential that can benefit the entire healthcare community, particularly in this difficult economic environment. We are very proud to be supporting this promising company's progress." Asanuma added, "We are a very selective investor and only make one or two new investments each year. Synageva qualifies with our solid and rigorous investment criteria in that they have excellent platform technologies, a strong product pipeline and an experienced management team."

Hunt BioVentures is a diversified investment firm with a primary focus on life science companies. As part of a privately held company with a highly-entrepreneurial culture, they are committed to working in partnership with the entrepreneur. In addition to providing capital, Hunt BioVentures provides the relationships, broad resources and operating experiences that arise from being part of an enterprise with worldwide interests in oil and gas, real estate, power, ranching and private investing. Hunt Bioventures, Inc. is a part of the family of companies owned by Ray L. Hunt of Dallas, Texas.

(more)

## About Synageva BioPharma

Synageva BioPharma Corp., is a biopharmaceutical company dedicated to developing and commercializing novel, next generation, and follow-on protein therapeutics that leverage the unique competitive advantages of its proprietary Synageva Expression Platform (SEP™). Synageva's development programs address specific unmet medical or market needs in several therapeutic areas, including oncology, organ dysfunction, autoimmune diseases and rare disorders. The Company has generated a diverse pipeline of product candidates, including high-potency monoclonal antibodies with potentially up to 100-fold increased killing activity for cancer targets, novel proteins for rare diseases, and next generation and follow-on cytokines.

SEP™ by Synageva is a novel, integrated platform of proprietary vectors and protein production, processing and purification systems. It provides a number of sustainable advantages over current expression systems for developing and commercializing protein therapeutics, including: high expression levels, more efficient purification processes, rapid scalability, consistency of end product, substantially reduced costs, and the ability to produce certain proteins with the potential for improved activity and/or safety profiles. Synageva has leveraged these attributes to develop its pipeline of biopharmaceuticals, including monoclonal antibodies with significant potency and potential efficacy advantages.

Further information regarding Synageva BioPharma Corp. is available at [www.synageva.com](http://www.synageva.com).

xxx

Contact:  
Chris Heberlig  
Director of Finance and Administration  
Synageva BioPharma Corp.  
60 Hickory Drive  
Waltham, MA 02451  
(781) 890-1111  
[chris.heberlig@synageva.com](mailto:chris.heberlig@synageva.com)